2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.
Related Content: